CC-97540
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for CC-97540, covering 2024-05-20 to 2026-02-10. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) [Phase 1]